Bayer puts part of Roundup settlement on hold

FRANKFURT (Reuters) – Bayer <BAYGn.DE> has agreed to delay part of a proposed settlement of allegations that its widely used weedkiller Roundup caused cancer after a U.S. judge questioned its plan to deal with future claims.

The German company said on Wednesday that lawyers representing those preparing a class action had withdrawn a request for court approval of the $1.25 billion scheme, part of a broader $10.9 billion agreement to settle close to 100,000 U.S. lawsuits related to Roundup.

The move would give the parties more time to address questions raised by Federal District Court Judge Vince Chhabria of the Northern District of California who presides over the federal Roundup litigation, Bayer said in a statement.

“Bayer remains strongly committed to a resolution that simultaneously addresses both the current litigation on reasonable terms and a viable solution to manage and resolve potential future litigation”, it added.

It declined to comment on the impact of the withdrawal on the timetable for the rest of the settlement.

Bayer is seeking to end legal disputes it inherited with its $63 billion takeover of Monsanto in 2018.

Bayer shares were down 1.2% by 1307 GMT.

On Tuesday, Bayer shares had fallen more than 6% after Chhabria said that the court was inclined to oppose the part of the proposed settlement that deals with future claims. The case was due to be considered again on July 24.

Bayer had planned to create an independent panel of scientific experts to help assess whether glyphosate caused cancer.

But in a filing published on July 6, Chhabria had questioned the idea of delegating the decision from judges and juries to a panel of scientists.

Chhabria also questioned whether potential claimants would want to remain bound by a ruling reached by the proposed scientific panel if research is still ongoing.

Regulators including the U.S. Environmental Protection Agency and the European Chemicals Agency, have determined glyphosate to be non-carcinogenic, supporting Bayer’s claim that the active ingredient in its Roundup product is safe for agricultural use.

However, in 2015, the World Health Organization’s cancer research arm determined the herbicide to be a “probable carcinogen”, and since 2018, three consecutive U.S. juries, who listened to scientific evidence from both sides during trials, found that Roundup causes cancer.

(Reporting by Arno Schuetze; Editing by Keith Weir)

U.S. judge affirms Monsanto weed-killer verdict, slashes damages

Monsanto's Roundup weedkiller atomizers are displayed for sale at a garden shop near Brussels, Belgium November 27, 2017. REUTERS/Yves Herman

By Tina Bellon

(Reuters) – A U.S. judge on Monday affirmed a verdict against Bayer AG unit Monsanto that found its glyphosate-based weed-killers responsible for a man’s terminal cancer, sending the German company’s shares down 8 percent.

In a ruling by San Francisco’s Superior Court of California, Judge Suzanne Bolanos said she would slash the punitive damages award to $39 million from $250 million if lawyers for school groundskeeper Dewayne Johnson agreed.

Bayer said in a statement the decision to reduce the damages was a step in the right direction, but it would still file an appeal with the California Court of Appeal because the verdict was not supported by the evidence presented at the trial.

“According to an earlier hearing, the judge toyed with the idea of dropping the damages altogether,” brokerage alpha said in a note to clients. “Now, however, the judge made a U-turn and confirmed the jury’s previous verdict.”

Monsanto, which denies the allegations, had asked the judge to throw out the entire original $289 million verdict or order a new trial on the punitive damages portion.

A jury on Aug. 10 found the company’s glyphosate-based weed-killers, including RoundUp and Ranger Pro, had caused Johnson’s cancer and that the company failed to warn consumers about the risks.

The verdict wiped 10 percent off the value of the company and marked the first such decision against Monsanto, which faces more than 8,000 similar lawsuits in the United States.

Plaintiff Dewayne Johnson leaves the courtroom following a post-trial hearing at the Superior Court in San Francisco, California, U.S., October 10, 2018. REUTERS/Jim Christie

Plaintiff Dewayne Johnson leaves the courtroom following a post-trial hearing at the Superior Court in San Francisco, California, U.S., October 10, 2018. REUTERS/Jim Christie

The German company, which bought Monsanto this year for $63 billion, says decades of scientific studies and real-world use have shown glyphosate to be safe for human use.

Lawyers for Johnson in a statement on Monday said they were still reviewing whether to accept the reduced award or retry the punitive damages portion.

“The evidence presented to this jury was, quite frankly, overwhelming,” the lawyers said.

The amount of punitive damages is limited by law, and Bolanos said California’s constitution did not permit a higher award. If Johnson accepts the reduced damages, the final verdict would order Monsanto to pay a total of $78 million, split equally between compensatory and punitive damages.

Bolanos’ Monday decision is a turnaround from a previous tentative ruling she issued on Oct. 10.

In that preliminary order, Bolanos said she was considering ordering a new trial on punitive damages, saying Johnson had failed to meet his burden of producing clear and convincing evidence of malice or oppression by Monsanto, a requirement for allowing a jury to award punitive damages.

But following that tentative ruling, at least five of the jurors who delivered the Aug. 10 verdict sent letters to the judge, urging her to uphold their decision. Bolanos did not directly refer to the jurors’ letters in her Monday ruling but said the jury was entitled to its findings.

In September 2017, the U.S. Environmental Protection Agency concluded a decades-long assessment of glyphosate risks and found that the chemical was not a likely carcinogen to humans.

However, in 2015, the cancer unit of the World Health Organisation classified glyphosate as “probably carcinogenic to humans.”

Johnson’s case, filed in 2016, was fast-tracked for trial due to the severity of his non-Hodgkin’s lymphoma, a cancer of the lymph system, that he alleged was caused by years of glyphosate exposure.

(Additional reporting by Ismail Shakil in Bengaluru and Arno Schuetze in Frankfurt; editing by Robert Birsel)